Underwriting Agreement
On October 13, 2022, VectivBio Holding AG (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, SVB Securities LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of 16,700,000 ordinary shares of the Company, with a nominal value CHF 0.05 per share (the “Shares”), at an offering price of $7.50 per share. Gross proceeds, before deducting underwriting discounts and commissions and other offering expenses, from the Offering are expected to be $125.25 million. The Shares in the Offering were offered pursuant to a registration statement on Form F-3 (File No. 333-264653), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 4, 2022 and declared effective by the SEC on May 12, 2022, as supplemented by a prospectus supplement filed with the SEC on October 14, 2022, pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). Jefferies LLC, SVB Securities LLC and Piper Sandler & Co. acted as joint book-running managers for this Offering.
The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, and other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Underwriting Agreement.
The foregoing summary of the Underwriting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the Underwriting Agreement, which is filed herewith as Exhibit 1.1 and incorporated herein by reference.
The legal opinion of Homburger AG relating to the legality of the Shares issued in the Offering is filed as Exhibit 5.1 to this report on Form 6-K.
Amended Articles of Association
On October 17, 2022, in connection with the Offering, the Company amended its Articles of Association (the “Articles of Association”) to account for the Shares issued in the Offering. A copy of the Company’s amended Articles of Association is filed as Exhibit 1.2 to this report on Form 6-K. The foregoing summary of the Company’s amended Articles of Association does not purport to be complete and is subject to, and qualified in its entirety by, the amended Articles of Association, which are filed herewith as Exhibit 1.2 and incorporated herein by reference.
Pricing Press Release
On October 13, 2022, the Company issued a press release announcing the pricing of the Offering, a copy of which is furnished as Exhibit 99.1 to this report on Form 6-K.
Closing Press Release
On October 18, 2022, the Company issued a press release announcing the closing of the Offering, a copy of which is furnished as Exhibit 99.2 to this report on Form 6-K.
Incorporation by Reference
The Company hereby incorporates by reference the information contained in the body of this Report on Form 6-K into the Company’s registration statements on Form S-8 (File No. 333-255524) and Form F-3 (File No. 333-264653) (including any prospectuses forming a part of such registration statements) and deems it to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
